Clinical research

SURMOUNT-3: Tirzepatide after intensive lifestyle intervention

Released: · Last reviewed: · By Dr. Parmis

Phase 3 randomised placebo-controlled trial following an intensive lifestyle intervention lead-in. 806 randomised, over 72 weeks. Sponsor: Eli Lilly and Company.

SURMOUNT-3 (NCT04657016) tested at Maximum tolerated, 10 or 15 mg against placebo in adults with overweight or obesity who completed a 12-week intensive lifestyle intervention.−18.4% additional reduction versus +2.5% with placebo, on top of lead-in weight loss Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

DesignPhase 3 randomised placebo-controlled trial following an intensive lifestyle intervention lead-in
PopulationAdults with overweight or obesity who completed a 12-week intensive lifestyle intervention
Sample size806 randomised
InterventionNot stated (Maximum tolerated, 10 or 15 mg)
ComparatorPlacebo
Duration72 weeks
Primary endpointPercentage change in body weight after a 12-week intensive lifestyle lead-in
SponsorEli Lilly and Company

Results

−18.4% additional reduction versus +2.5% with placebo, on top of lead-in weight loss

Reported change by arm (chart data rendered as a table for accessibility)
ArmReported change
Tirzepatide, additional18.4%

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

Industry-funded. The lifestyle lead-in selects for people who already responded to lifestyle intervention, which limits generalisability.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Sources

  1. Wadden TA et al., Nature Medicine 2023. NCT04657016 (source URL not published — treat as unverified) — Peer-reviewed publication
  2. SURMOUNT-3 — ClinicalTrials.gov record NCT04657016 — Trial registry record
  3. PubMed search: SURMOUNT-3 — Literature database search, checked November 21, 2026
  4. DailyMed (NLM): Zepbound (tirzepatide) prescribing information — FDA-approved label database, checked November 21, 2026
  5. DailyMed (NLM): Mounjaro (tirzepatide) prescribing information — FDA-approved label database, checked November 21, 2026

Cite this page

GLP Ranked. "SURMOUNT-3: Tirzepatide after intensive lifestyle intervention." https://glpranked.com/research/surmount-3/

GLP Ranked. "SURMOUNT-3: Tirzepatide after intensive lifestyle intervention." https://glpranked.com/research/surmount-3/